SCHEDULE: BlackRock Reports Stake in Myriad Genetics

BlackRock Portfolio Management LLC has updated its beneficial ownership filing for Myriad Genetics Inc., reporting a 10.4% stake.

Summary

• BlackRock Portfolio Management LLC has filed a Schedule 13G, indicating a change in its beneficial ownership of Myriad Genetics Inc. common stock.
• The filing reports that BlackRock Portfolio Management LLC beneficially owns 9,900,937 shares, representing 10.4% of the class of securities.
• This ownership includes sole voting power over 8,751,792 shares and sole dispositive power over 9,900,937 shares.
• The filing is made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
• The date of the event requiring the filing was August 31, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake (10.4%) in Myriad Genetics Inc., which can be interpreted as a sign of confidence in the company's long-term prospects.
• The filing is a routine disclosure, indicating compliance with regulatory requirements for significant shareholders.

Negatives

• The filing does not provide any new operational or financial performance data for Myriad Genetics Inc., limiting insights into the company's current health.
• The information is solely related to beneficial ownership, not necessarily active management or strategic involvement by BlackRock.

Risks

• The filing does not explicitly mention any risks associated with Myriad Genetics Inc. or BlackRock's investment.
• Potential risks for investors in Myriad Genetics Inc. could include market competition, regulatory changes in the genetic testing industry, and the company's ability to innovate and commercialize its products.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Myriad Genetics Inc.'s future performance.

Management Comments

• BlackRock Portfolio Management LLC, in accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
• Spencer Fleming, Managing Director, certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is a standard Schedule 13G disclosure, common for large institutional investors like BlackRock when their beneficial ownership of a public company's stock crosses a reporting threshold. It signifies BlackRock's position as a significant shareholder in the genomics and diagnostics sector, an industry characterized by rapid innovation and evolving regulatory landscapes.

Comparison to Industry Standards

• As a Schedule 13G filing, it adheres to the reporting standards set by the U.S. Securities and Exchange Commission for institutional investors.
• The 10.4% ownership stake by BlackRock is a substantial position, often indicative of a passive investment strategy by a large asset manager, common among firms like Vanguard or Fidelity when holding similar stakes in other companies within the healthcare or technology sectors.

Stakeholder Impact

• Shareholders of Myriad Genetics Inc.: The filing confirms BlackRock as a significant institutional shareholder, which may provide some stability or influence in corporate matters.
• BlackRock Investors: The filing details the extent of BlackRock's investment in Myriad Genetics Inc., informing their portfolio management decisions.

Next Steps

• BlackRock Portfolio Management LLC will continue to monitor its beneficial ownership of Myriad Genetics Inc. and file amendments to this Schedule 13G as required by SEC regulations.
• Myriad Genetics Inc. will continue its operations and strategic initiatives, subject to market conditions and industry trends.

Key Dates

Keywords

Myriad Genetics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing